Is the immune response to influenza vaccination in obese children the same as in normal weight children

Influenza vaccination in obese children - OFICE

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2018-004386-14-IS

Enrollment

Registered

2024-03-06

Start date

2020-10-02

Completion date

Unknown

Last updated

2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relationship between obesity and immune responses

Interventions

Trade Name: Influvac Product Name: Influvac Product Code: FluVacc Pharmaceutical Form: Suspension for injection in pre-filled syringe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Study group: BMI > 30 Control group: BMI =65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Failure to supply informed consent Immune suppression, allergy to vaccine components or any other contraindication to receiving the vaccines.

Design outcomes

Primary

Measure	Time frame
Main Objective: To study immune responses to influenza vaccine in obese children in comparison to normal weight children.;Secondary Objective: To ascertain if any particular aspects of obesity, i.e. waist circumference, fat percentage or BMI as continious variables or sex, age and ethnicity as categorical variables are associated with differences in vaccine responses.;Primary end point(s): GMT titres to influenza vaccine. Fourfold increase in titre post-vaccination compared with pre-vaccination;Timepoint(s) of evaluation of this end point: Bloods are drawn at the time of vaccination (pre-vaccination status) and repeated 4 weeks after vaccination (post-vaccination).	—

Measure

Time frame

Main Objective: To study immune responses to influenza vaccine in obese children in comparison to normal weight children.;Secondary Objective: To ascertain if any particular aspects of obesity, i.e. waist circumference, fat percentage or BMI as continious variables or sex, age and ethnicity as categorical variables are associated with differences in vaccine responses.;Primary end point(s): GMT titres to influenza vaccine. Fourfold increase in titre post-vaccination compared with pre-vaccination;Timepoint(s) of evaluation of this end point: Bloods are drawn at the time of vaccination (pre-vaccination status) and repeated 4 weeks after vaccination (post-vaccination).

—

Secondary

Measure	Time frame
Secondary end point(s): Multivariable modelling of risk factors for differences in immune responses;Timepoint(s) of evaluation of this end point: 4 weeks post immunisation	—

Countries

Iceland

Contacts

Public ContactPrimary investigator

Landspitali University Hospital

valtyr@landspitali.is

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026